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Abstract Upon epidermal growth factor treatment, phospholi-
pase C-Q1 (PLC-Q1) translocates from cytosol to membrane
where it is phosphorylated at tyrosine residues. Caveolae are
small plasma membrane invaginations whose structural protein is
caveolin. In this study, we show that the translocation of PLC-Q1
and its tyrosine phosphorylation are localized in caveolae by
caveolin-enriched low-density membrane (CM) preparation and
immunostaining of cells. Pretreatment of cells with methyl-L-
cyclodextrin (MLCD), a chemical disrupting caveolae structure,
inhibits the translocation of PLC-Q1 to CM as well as
phosphatidylinositol (PtdIns) turnover. However, MLCD shows
no effect on tyrosine phosphorylation level of PLC-Q1. Our
findings suggest that, for proper signaling, PLC-Q1 phosphoryla-
tion has to occur at PtdInsP2-enriched sites. ß 2001 Federa-
tion of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
Phospholipase C-Q (PLC-Q) hydrolyzes phosphatidylinositol
4,5-bisphosphate (PtdInsP2), and one product of this hydro-
lysis, inositol 1,4,5-trisphosphate, mobilizes Ca2 from the
intracellular stores, while the other product of the hydrolysis,
1,2-diacylglycerol, is an activator of protein kinase C [1]. It
has been suggested that in A431 cells, or other cultured cells
that express high levels of the human epidermal growth factor
(EGF) receptor, it is the tyrosine phosphorylation of PLC-Q
by the EGF receptor that is responsible for the EGF-stimu-
lated inositol phosphate production [2,3]. It has also been
reported that stimulation of A431 cells with EGF leads to
the translocation of PLC-Q1 from cytosol to membrane [4].
Caveolae are 50^100 nm sized plasma membrane invagina-
tions where cholesterol and glycosphingolipids are concen-
trated, making these domains resistant to extraction by Triton
X-100 [5,6]. Caveolin, a 21^24 kDa integral membrane pro-
tein, is a major structural component of the caveolae [7].
Caveolae can be isolated as a low-density membrane fraction
where caveolin is enriched, denoted by CM (caveolin-enriched
low-density membrane), by sucrose density step gradient cen-
trifugation [8,9]. It has been suggested that caveolae may
function as subcellular compartments in which to store inac-
tive signaling molecules for regulated activation and to facil-
itate cross-talk between distinct signaling cascades [10,11].
Many proteins involved in signal transduction have been
found in CM, such as heterotrimeric G proteins, Src family
kinases, platelet-derived growth factor receptors, and EGF
receptors [6,12^14]. It has been reported that in A431 cells
approximately half of the total cellular PtdInsP2 is localized
in CM [15]. The cholesterol binding agent methyl-L-cyclodex-
trin (MLCD), which has been reported to cause the loss of
compartmentalization of molecules in caveolae [16,17], deloc-
alizes PtdInsP2 from CM [12]. In this paper, we show that
EGF-induced translocation and tyrosine phosphorylation of
PLC-Q1 are both localized in CM. Immunostaining of cells
also shows a co-localization of PLC-Q1 and caveolin-1 after
EGF stimulation. MLCD pretreatment of the cells inhibits
PLC-Q1 translocation to CM and phosphatidylinositol
(PtdIns) turnover. But MLCD has no e¡ect on the phosphor-
ylation of PLC-Q1. These results suggest that the co-localiza-
tion of the PLC-Q1 phosphorylation and its substrate at an
enriched site is required for proper PLC-Q1 signaling.
2. Materials and methods
2.1. Antibodies and chemicals
For Western blot analysis, anti-caveolin-1 (C13620) antibody, anti-
£otillin antibody, and anti-EGF receptor antibody were from Trans-
duction Laboratories. Anti-PLC-Q1 monoclonal antibody and anti-
phosphotyrosine monoclonal antibody were prepared as described
previously [18]. For immunostaining of cells, anti-caveolin-1 polyclon-
al antibody (cat # sc-894) was from Santa Cruz Biotech, Inc., and
rhodamine-conjugated goat anti-rabbit antibody (PN 31670) was from
Pierce. Anti-PLC-Q1 monoclonal antibody was conjugated with FITC
by ABI (Chonju, South Korea). EGF was obtained from the Dae-
woong Pharmaceutical Company (Seoul, South Korea). Myo-
[3H]inositol was from Amersham Pharmacia Biotech. All other chem-
icals were from Sigma.
2.2. Cell culture
A431 cells were cultured in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) supplemented with 10% bovine calf serum. Cells were se-
rum-starved for 24 h before use in the experiments. Cells were pre-
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incubated with phosphatase inhibitor (sodium vanadate, activated, 0.1
mM, 37‡C, 10 min), and EGF treatment (100 ng/ml) was performed
for 2 min at 37‡C. MLCD (5 mM) pretreatment was given for 30 min
at 37‡C before the preincubation with sodium vanadate. COS-7 cells
were cultured in DMEM supplemented with 10% fetal bovine serum.
2.3. Detergent-free isolation of caveolin-enriched membranes
Caveolin-enriched membrane fractions were prepared as described
previously [9]. A431 cells (one or two 150-mm dishes) were suspended
in 2 ml of 500 mM sodium carbonate bu¡er, pH 11. Sodium vanadate
(1 mM) was present at all steps. The cell suspension was homogenized
with 10 strokes of a Dounce homogenizer, three 10-s bursts of a
Polytron tissue grinder, and three 20-s bursts of a sonicator. The
homogenate was then adjusted to 45% sucrose by addition of 80%
sucrose prepared in MES bu¡er (25 mM MES, pH 6.5, 150 mM
NaCl, 1 mM EGTA, 1 mM Na3VO4) and placed into ultracentrifu-
gation tubes so that each tube would contain the same amount of
protein. A 5^35% discontinuous sucrose gradient (both in MES bu¡-
er) was then formed on top. The samples were centrifuged at 39 000
rpm for 6 h in an SW41 rotor (Beckman Instruments). Fractions were
collected from the top in 1 ml amounts except for fractions 4 and 13,
which were collected as 0.5 ml fractions.
2.4. Membrane precipitation and Western blot analysis
100 Wl of CM and 450 Wl of non-caveolae containing membrane
(non-CM) fraction, prepared by pooling fractions 9^13, were diluted
¢ve times with MES bu¡er and then centrifuged at 100 000Ug for 1 h.
Supernatants were discarded and pellets were analyzed by Western
blotting after SDS^PAGE (6^16%). Horseradish peroxidase-conju-
gated secondary antibody (1:5000 dilution; KPL) and an enhanced
chemiluminescence assay kit (Amersham Life Sciences) were used to
visualize the bands.
2.5. Immunoprecipitation of PLC-Q1
CM and non-CM preparations were resuspended in 1 ml of ex-
traction bu¡er (10 mM Tris^HCl, pH 7.4, 1% Triton X-100, 0.5%
NP-40, 60 mM L-octylglucoside, 1 mM EDTA, 1 mM EGTA, 1 mM
Na3VO4) and sonicated. Insoluble material was removed by centrifug-
ing at 15 000Ug for 15 min and the supernatant incubated for 2 h at
4‡C with anti-PLC-Q1 IgG [18] prebound to pansorbin. The immune
complexes were collected and washed three times with extraction bu¡-
er. The precipitates were then resuspended in 30 Wl of SDS^PAGE
sample bu¡er and subjected to electrophoresis and Western blot anal-
ysis. To determine the e¡ect of MLCD on PLC-Q1 tyrosine phosphor-
ylation, 1 mg of A431 cell lysate in extraction bu¡er was incubated
with anti-PLC-Q1 IgG [18] prebound to Protein A-Sepharose beads.
The following procedures were as described above.
2.6. Immunostaining of COS-7 cells
2U105 COS-7 cells were transfected with 0.5 Wg DNA of PLC-Q1
[27] using LipofectAMINE following the manufacturer’s instructions.
Cells were serum-starved for 24 h before use in the experiments. EGF
treatment (100 ng/ml) was performed for 5 min at 37‡C. Cells were
washed with phosphate-bu¡ered saline (PBS) and ¢xed for 10 min at
room temperature with 3.7% paraformaldehyde in PBS. Fixed cells
were rinsed with PBS and permeabilized with 0.2% Triton X-100 in
PBS for 10 min. Cells were rinsed with PBS and incubated with block-
ing solution (2% bovine serum albumin and 100 Wl/ml equine serum in
PBS) for 1 h at room temperature. Cells were then incubated over-
night at 4‡C with anti-caveolin-1 polyclonal antibody diluted 1/200
with blocking solution. After washing six times with PBS (10 min
each), cells were incubated with FITC-conjugated anti-PLC-Q1 mono-
clonal antibody (1.5 Wg/ml in blocking solution) and rhodamine-con-
jugated goat anti-rabbit antibody (diluted 1/1000 with blocking solu-
tion after reconstitution). Then cells were washed six times with PBS
(10 min each). Slides were mounted and examined by a £uorescence
microscope (Nikon, Inc., Melville, NY, USA).
2.7. Preparation of cholesterol^MLCD complexes
Cholesterol^MLCD complexes were prepared as described by Pike
et al. [12]. Brie£y, 6 mg of cholesterol was dissolved in 80 Wl of iso-
propyl alcohol:chloroform (2:1). MLCD (200 mg) was dissolved in
2.2 ml of water and heated to 80‡C with stirring in a water bath. The
cholesterol was then added in small aliquots and the solution stirred
until clear. This solution contained 6.8 mM cholesterol.
Fig. 1. PLC-Q1 is present in the CM fraction. A431 cells in 150-mm
plates were harvested after 12 h of serum starvation into 500 mM
Na2CO3, pH 11, homogenized, and fractionated by sucrose density
gradient centrifugation as described in Section 2. Fractions were col-
lected from the top, and 20 Wl aliquots from each fraction were sub-
jected to SDS^PAGE followed by Western blot analysis with the in-
dicated antibodies. Caveolae are enriched in fraction 5. Fractions 9^
13 were pooled for the non-caveolae membrane (non-CM) fraction.
Fig. 2. PLC-Q1 translocation and tyrosine phosphorylation are local-
ized in the CM fraction. A: The 100 ng/ml EGF stimulation was
performed at 37‡C for 2 min. To exclude cytosolic proteins in the
non-caveolae membrane (non-CM) fraction, 100 Wl of CM and 450
Wl of the non-CM fraction were diluted ¢ve times with MES bu¡er
and centrifuged at 100 000Ug for 1 h. Supernatants were discarded,
and pellets were resuspended in 30 Wl SDS^PAGE sample bu¡er
and subjected to Western blot analysis. B: Pellets prepared as in A
were extracted with extraction bu¡er and subjected to immunopre-
cipitation with anti-PLC-Q1 monoclonal antibody. The immunopre-
cipitated complexes were analyzed by Western blot analysis. 6 in-
dicates the region corresponding to the molecular weight of PLC-Q1.
C: Densitometric analysis of translocated PLC-Q1 in CM and non-
CM. The blots in the lower panels of B underwent densitometry us-
ing the Molecular Analyst Software (Bio-Rad). Means þ S.E.M.
from two independent assays are shown. Columns marked by aster-
isks represent the controls.
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2.8. Measurement of PtdIns turnover
A431 cells were plated in six-well dishes. For labeling, con£uent
cultures were incubated in inositol-free DMEM containing 1 WCi/ml
myo-[3H]inositol but no serum for 24 h. The cells were then treated
with MLCD as described above followed by 20 mM LiCl pretreatment
for 10 min. Then the cells were stimulated with EGF (100 ng/ml) for
30 min. The reactions were terminated by aspiration of the medium
and addition of 400 Wl of 5% perchloric acid. After incubation on ice
for 30 min and centrifugation at 15 000Ug for 5 min, 10 Wl of the
supernatant was sampled and used to determine total [3H]inositol.
Inositol phosphates were isolated on an AG 1-X8 column as described
previously [19].
3. Results
3.1. Small amount of PLC-Q1 is found in CM of unstimulated
A431 cells
The homogenate of A431 cells after 12 h of serum starva-
tion was fractionated by sucrose density centrifugation in the
absence of detergent, a widely used method to isolate caveo-
lae-enriched membrane subdomains. As shown in Fig. 1, cav-
eolin, EGF receptor, and £otillin, which is caveolae-associated
integral membrane protein [14,20], were enriched in fraction 5.
Fraction 5 was therefore selected as the caveolae fraction,
denoted by CM, and fractions from 9 to 13 were pooled as
the non-caveolae membrane (non-CM) fraction. Only a minor
amount of PLC-Q1 was detected in the CM fraction (Fig. 1).
3.2. Translocation and tyrosine phosphorylation of PLC-Q1
occurs only in CM
The CM fraction and non-CM fraction were pelleted at
100 000Ug to exclude cytosolic proteins. Upon treatment of
the cells with EGF, the translocation of PLC-Q1 to the mem-
brane was observed mainly in CM (Fig. 2A). CM and non-
Fig. 3. Immunostaining of COS-7 cells shows the co-localization of PLC-Q1 and caveolin-1 after EGF treatment. COS-7 cells were transfected
with PLC-Q1. At 24 h after transfection, the cells were starved for 24 h prior to stimulation with EGF for 5 min. Then the cells were ¢xed and
stained with anti-caveolin-1 antibody. Rhodamine-conjugated anti-rabbit antibody was used as a secondary antibody for staining of caveolin-1,
and FITC-conjugated anti-PLC-Q1 antibody was used to visualize PLC-Q1. The yellow spots of the merged image in the lower panel indicate
the co-localization of PLC-Q1 and caveolin-1 after EGF treatment. Bar, 10 Wm.
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CM were treated with anti-PLC-Q1 monoclonal antibody and
the immunoprecipitates were probed with anti-phosphotyro-
sine antibody. Phosphorylated PLC-Q1 was exclusively de-
tected in the CM fraction (Fig. 2B). Since tyrosine phosphor-
ylation of PLC-Q1 is critically required for this enzyme’s
activation in vivo [21], our results suggest that the enzymatic
activation of PLC-Q1 is localized in CM.
3.3. Immunostaining of COS-7 cells shows the co-localization
of PLC-Q1 and caveolin-1 after EGF stimulation
We showed that PLC-Q1 translocates to CM (Fig. 2), but it
was not sure that the CM fraction contains caveolae only.
Therefore, to investigate the PLC-Q1 translocation further,
we stained COS-7 cells after transfection of PLC-Q1. As shown
in Fig. 3, PLC-Q1 (green) translocates from cytosol to plasma
membrane after EGF stimulation. Caveolin-1 (red) is a struc-
tural protein of caveolae. Merged images show the co-local-
ization (yellow) of PLC-Q1 and caveolin-1 in the plasma mem-
brane after EGF treatment, which tells that PLC-Q1
translocates to caveolae upon EGF stimulation.
3.4. MLCD pretreatment inhibits PLC-Q1 translocation to CM
and PtdIns turnover
Depletion of cellular cholesterol by MLCD was reported to
cause the loss of compartmentalization of signaling molecules
in caveolae [12]. To determine what e¡ect the disruption of
the caveolar structure would have on PLC-Q1 signaling, we
treated the cells with MLCD before EGF stimulation. As
seen in Fig. 4A, MLCD pretreatment delocalized EGF recep-
Fig. 4. MLCD pretreatment inhibits EGF-stimulated PLC-Q1 trans-
location to CM and PtdIns turnover. A: After serum starvation,
A431 cells were preincubated with or without 5 mM MLCD for 30
min at 37‡C. The medium of one MLCD-treated culture was re-
moved and replaced with 0.2 mM cholesterol complex with MLCD
for 30 min at 37‡C. EGF stimulation was performed and the cells
were subjected to a detergent-free method of isolating the caveolin-
enriched membranes. 100 Wl of the CM fraction was diluted ¢ve
times with MES bu¡er and centrifuged at 100 000Ug for 1 h.
Supernatants were discarded, and pellets were resuspended in 30 Wl
of SDS^PAGE sample bu¡er, electrophoresed, and analyzed by
Western blotting. B: A431 cells were labeled with [3H]inositol and
then switched into inositol-free DMEM. MLCD treatment and cho-
lesterol add-back were performed as described above. Then the cells
were treated with 20 mM LiCl for 10 min at 37‡C. Subsequently
the cultures were stimulated with 100 ng/ml EGF for 30 min at
37‡C. [3H]Inositol phosphates were isolated as described in Section 2.
Data shown represent the means þ S.E.M. of duplicate determina-
tions.
Fig. 5. MLCD has no e¡ect on the phosphorylation of EGF recep-
tor and PLC-Q1. A: A431 cells were incubated with 5 mM MLCD
for 30 min at 37‡C before 0.1 mM sodium vanadate was added for
10 min. Subsequently the cultures were stimulated with 100 ng/ml
EGF for 2 min at 37‡C. 600 Wl extraction bu¡er was added to 1 mg
of cells, and 20 Wl aliquots were subjected to SDS^PAGE followed
by Western blot analysis with anti-EGF receptor antibody and anti-
phosphotyrosine antibody. 6 indicates the region corresponding to
the molecular weight of the EGF receptor. B: The cell lysates pre-
pared in A were incubated with anti-PLC-Q1 monoclonal antibody.
The immunoprecipitated complexes were analyzed by Western blot
analysis with anti-PLC-Q1 antibody and anti-phosphotyrosine anti-
body. 6 indicates the region corresponding to the molecular weight
of PLC-Q1. C: The blots in A and B underwent densitometry using
the Molecular Analyst Software (Bio-Rad). In determining the
MLCD e¡ect on EGF receptor phosphorylation, the integrated den-
sities of blots in the lower panel of A were divided by the integrated
densities of blots in the upper panel of A. In determining MLCD ef-
fect on PLC-Q1 phosphorylation, the integrated densities of blots in
the lower panel of B were divided by the integrated densities of
blots in the upper panel of B. Means þ S.E.M. from two indepen-
dent assays are shown. Columns marked by asterisks represent the
controls.
FEBS 24613 19-2-01 Cyaan Magenta Geel Zwart
I.-H. Jang et al./FEBS Letters 491 (2001) 4^8 7
tor and caveolin-1 from CM. And MLCD pretreatment inhib-
ited EGF-induced PLC-Q1 translocation to CM (Fig. 4A) and
PtdIns turnover (Fig. 4B). The inhibition was recovered when
cholesterol was added back, which tells that MLCD e¡ects
were not simply the artifacts caused by its cellular toxicity.
These results suggest that the integrity of caveolae is impor-
tant for PLC-Q1 signaling.
3.5. MLCD pretreatment has no e¡ect on the phosphorylation
of the EGF receptor and PLC-Q1
It has previously been reported that MLCD treatment de-
localizes the EGF receptor and PtdInsP2 from CM [12,22].
Our data show that the MLCD pretreatment of cells prevents
the PLC-Q1 translocation to CM (Fig. 4A). Thus we expected
that the inhibition of the PtdIns turnover could be the con-
sequence of the loss of co-localization of the molecules in-
volved. Still, it was not clear which step of the PLC-Q1 signal-
ing would be a¡ected. The inhibition of PtdIns turnover could
be due to a decrease in EGF receptor tyrosine phosphoryla-
tion, a decrease in PLC-Q1 tyrosine phosphorylation, the de-
localization of the substrate PtdInsP2, or a combination of all
of those events. In order to test these possibilities, we checked
the e¡ects of MLCD pretreatment on the phosphorylation
level of the EGF receptor and PLC-Q1 using Western blot
analysis. As seen in Fig. 5, there was no decrease in the tyro-
sine phosphorylation level of the EGF receptor or PLC-Q1.
These ¢ndings suggest that the inhibition of the PtdIns turn-
over by the disruption of the caveolar structure is not a result
of a failure in EGF receptor phosphorylation or PLC-Q1 phos-
phorylation. It is more likely a result of delocalization of
PtdInsP2.
4. Discussion
Caveolae are sites where many signaling molecules come
together. Caveolae can be isolated as CM fraction. In this
study, we show that the EGF receptor is found highly en-
riched in CM (Fig. 1) and the translocation and tyrosine
phosphorylation of PLC-Q1 by EGF occur mainly in CM
(Fig. 2). We also show that translocated PLC-Q1 and caveo-
lin-1 are co-localized in the plasma membrane after EGF
stimulation by immunostaining of cells (Fig. 3). PLC-Q1 is a
substrate of the EGF receptor kinase [23], and many reports
have suggested that the EGF receptor is localized in the cav-
eolae [11,12,22,24,25]. Tyrosine phosphorylation of PLC-Q1 by
the EGF receptor is crucial for the enzymatic activation of
PLC-Q1 [21,26]. We therefore propose that the EGF-induced
PLC-Q1 translocation and enzymatic activation are localized
in the caveolae.
While the MLCD pretreatment of cells a¡ected the integrity
of the caveolae and inhibited the EGF-stimulated PtdIns turn-
over (Fig. 4), it was still not clear which step of the PLC-Q1
signaling was abrogated. Since the translocation of PLC-Q1 to
CM was inhibited upon MLCD pretreatment (Fig. 4), a de-
crease in PLC-Q1 tyrosine phosphorylation was expected.
However, we did not observe a decrease in the PLC-Q1 phos-
phorylation after MLCD pretreatment in EGF-stimulated
A431 cells (Fig. 5). This suggests that the EGF receptor can
phosphorylate PLC-Q1 properly even when the EGF receptor
is delocalized from CM. Then, why was PtdIns turnover in-
hibited? There have been reports that about 50% of the total
cellular PtdInsP2 is concentrated in CM [15] and that MLCD
pretreatment delocalizes PtdInsP2 from CM [12]. These re-
ports and our ¢ndings together suggest that the inhibition
of the PtdIns turnover by the disruption of the caveolar struc-
ture is due to the delocalization of PtdInsP2 and not a result
of a failure in PLC-Q1 phosphorylation. We propose that the
PLC-Q1 phosphorylation occurs at the PtdInsP2-enriched site
of the caveolae resulting in more e⁄cient PtdIns turnover.
In summary, the data reported here demonstrate that the
translocation and tyrosine phosphorylation of PLC-Q1 are lo-
calized in the CM domain. And we suggest that the localiza-
tion of the PLC-Q1 phosphorylation at a site enriched in its
substrate is a requisite for proper signaling.
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